NO971229L - Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger - Google Patents

Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger

Info

Publication number
NO971229L
NO971229L NO971229A NO971229A NO971229L NO 971229 L NO971229 L NO 971229L NO 971229 A NO971229 A NO 971229A NO 971229 A NO971229 A NO 971229A NO 971229 L NO971229 L NO 971229L
Authority
NO
Norway
Prior art keywords
compound
formula
alkyl
radical
pharmaceutically acceptable
Prior art date
Application number
NO971229A
Other languages
English (en)
Norwegian (no)
Other versions
NO971229D0 (no
Inventor
Henry Uhlman Bryant
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO971229D0 publication Critical patent/NO971229D0/no
Publication of NO971229L publication Critical patent/NO971229L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO971229A 1994-09-20 1997-03-17 Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger NO971229L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,904 US5554628A (en) 1994-09-20 1994-09-20 Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs
PCT/US1995/012345 WO1996009051A1 (fr) 1994-09-20 1995-09-18 Procede permettant de minimiser l'effet uterotrophique du tamoxifene et de ses analogues

Publications (2)

Publication Number Publication Date
NO971229D0 NO971229D0 (no) 1997-03-17
NO971229L true NO971229L (no) 1997-03-17

Family

ID=23195869

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971229A NO971229L (no) 1994-09-20 1997-03-17 Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger

Country Status (16)

Country Link
US (1) US5554628A (fr)
EP (1) EP0702961B1 (fr)
JP (1) JPH10506111A (fr)
KR (1) KR970705999A (fr)
AT (1) ATE220919T1 (fr)
AU (1) AU692932B2 (fr)
CA (1) CA2200205A1 (fr)
CZ (1) CZ82097A3 (fr)
DE (1) DE69527480D1 (fr)
FI (1) FI971155A7 (fr)
HU (1) HUT77954A (fr)
MX (1) MX9702037A (fr)
NO (1) NO971229L (fr)
NZ (1) NZ294176A (fr)
RU (1) RU2158589C2 (fr)
WO (1) WO1996009051A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
AU8683398A (en) * 1997-08-07 1999-03-01 Eli Lilly And Company 1-{4-(substituted alkoxy)benzyl}naphthalene compounds having estrogen inhibitoryactivity
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
US20070066595A1 (en) * 2004-01-22 2007-03-22 Dodge Jeffrey A Selective estrogen receptor modulators
KR101311534B1 (ko) * 2010-12-27 2013-09-25 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
WO2012091425A2 (fr) * 2010-12-27 2012-07-05 전남대학교산학협력단 Composition contenant, comme principe actif, un analogue de 4-hydroxytamoxifène ou un sel pharmaceutiquement acceptable de celui-ci, destinée à la prévention ou au traitement des maladies associées au syndrome métabolique
WO2012119010A2 (fr) * 2011-03-01 2012-09-07 Indiana University Research And Technology Corporation Substances inhibitrices d'aromatase et procédé d'utilisation desdites substances pour le diagnostic, le traitement et la surveillance du cancer du sein
CN104203961B (zh) * 2012-03-05 2017-05-17 泽维尔大学 作为用于治疗乳腺癌的基于硼的4‑羟基他莫昔芬和因多昔芬前药
CZ305571B6 (cs) * 2014-01-29 2015-12-16 Smart Brain s.r.o. Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
EP0002097B1 (fr) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Dérivés de triphénylalcène, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
NZ200204A (en) * 1981-04-03 1985-05-31 Lilly Co Eli Benzothiophene derivatives and process for preparation
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Also Published As

Publication number Publication date
FI971155A0 (fi) 1997-03-19
EP0702961B1 (fr) 2002-07-24
MX9702037A (es) 1997-06-28
RU2158589C2 (ru) 2000-11-10
FI971155L (fi) 1997-03-19
ATE220919T1 (de) 2002-08-15
DE69527480D1 (de) 2002-08-29
JPH10506111A (ja) 1998-06-16
AU3686295A (en) 1996-04-09
CZ82097A3 (en) 1997-08-13
HUT77954A (hu) 1998-12-28
FI971155A7 (fi) 1997-03-19
NZ294176A (en) 1999-10-28
EP0702961A3 (fr) 1999-11-10
CA2200205A1 (fr) 1996-03-28
AU692932B2 (en) 1998-06-18
NO971229D0 (no) 1997-03-17
KR970705999A (ko) 1997-11-03
US5554628A (en) 1996-09-10
EP0702961A2 (fr) 1996-03-27
WO1996009051A1 (fr) 1996-03-28

Similar Documents

Publication Publication Date Title
DE69525699T2 (de) Naphthyl-Derivate, Zwischenprodukte, Verfahren, Zusammensetzungen, die sie enthalten
US5510498A (en) Benzothiophene compounds, intermediates, compositions, and methods
DE69526550T2 (de) 2-(4-Hydroxyphenyl)-benzothiophen-Derivate, Zubereitungen und Methoden zur Milderung der Symptome des post-menopausalen Syndroms
TW479056B (en) Pharmaceutical composition of benzothiophene compound for treatment of central nervous system disorders
EA023173B1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
CZ113797A3 (en) Pharmaceutical preparation and the use thereof
CZ179598A3 (cs) Nové metody a použití
WO2004058682A1 (fr) Modulateurs selectifs des recepteurs d'oestrogene
NO309564B1 (no) Forbindelser som er nyttige som östrogene midler, anvendelse av forbindelsene samt farmasöytiske preparater inneholdende forbindelsene
US5658931A (en) Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
EA015151B1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA012262B1 (ru) Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов
NO971229L (no) Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger
NO310186B1 (no) Naftyl og dihydronaftyl mellomprodukter, forbindelser, sammensetninger og anvendelse av forbindelsene
US5952350A (en) Naphthyl compounds and compositions, as estrogen receptor binding agents
EP0832881B1 (fr) Composés benzofluorène, intermédiaires, compositions et méthodes
CA2216592C (fr) Composes a base de benzothiophene, intermediaires, compositions et methodes
NO314229B1 (no) Benzotiofenforbindelser, mellomprodukter, sammensetninger, fremgangsmåter og anvendelse av samme
GB2312844A (en) A naphthyl compound for the treatment of immune-complex diseases
CZ9903552A3 (cs) Léčení poruch centrální nervové soustavy selektivními modulátory receptorů estrogenů